Plain-English translation of NCT06484985 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
This is an early-stage clinical trial testing a new oral medication called in patients with advanced cancers, including non-Hodgkin lymphoma, T-cell lymphoma, and solid tumors. The study will help doctors understand how safe the medication is, what doses work best, and whether it can help shrink tumors. This medication is given by mouth twice daily, and the dose will be gradually increased during the trial to find the safest and most effective level.
Many patients with advanced cancers don't respond well to standard treatments or can't tolerate them. This trial is looking for a new treatment option that might help these patients by testing whether this medication is safe enough and effective enough to pursue further.
You likely qualify if…
You likely don't qualify if…
You will take the oral medication by mouth twice daily (or once daily in some dosing schedules). The study has two main parts: first, doses will be gradually increased to find the safest level, and then a larger group of patients will take the best dose found. Throughout the trial, you will have regular clinic visits for blood tests, scans, and other assessments to monitor how the medication is working and check for side effects. The study involves close monitoring to ensure your safety.
AI-generated summary from trial data · Jun 24, 2026 · Not medical advice
China
Phase
Safety & dosing
Sponsor
Axter Therapeutics (Beijing) Co., Ltd
Enrollment target
~78 participants
Started
September 2024
Primary completion
March 2027
Age range
18 Years and older
Last updated on clinicaltrials.gov in January 2026.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Wilson Wang
Axter Therapeutics (Beijing) Co., Ltd
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.